The mechanisms involved may be related to the PPAR signaling pathway, and PI3K-Akt signaling pathway, so PPAR inhibitors and PI3K-Akt inhibitors can be tried in high-risk patients to have a better prognosis for HCC patients. This evidence concerns the gene AKT1 and hepatocellular carcinoma.